Background
Histamine (HA) is a neurotransmitter that participates in the sleep cycle, motor activity, synaptic plasticity and memory [
1]–[
5]. The adult mammalian brain contains somas of HA-producing neurons in the hypothalamic tuberomamillary nucleus, and its projections reach most of the CNS [
3],[
4],[
6]. HA exerts its actions through the activation of four G-protein-coupled receptors: H
1R-H
4R. H
1R, H
2R and H
3R are widely distributed throughout the CNS [
6]–[
8], but the presence of H
4R in the brain remains unclear [
9]–[
11].
During embryonic development, HA is present at higher concentrations than those observed in the adult brain [
12]–[
14]. HA increases its content at embryonic days (E) 14–16, and then decreases perinatally [
13],[
15]–[
17]. Histidine decarboxylase (HDC), which synthetizes HA, and the mRNAs for H
1R, H
2R and H
3R [
18]–[
21] are also expressed at these developmental stages [
20],[
22],[
23]. The transitory expression of HDC in the midbrain, together with elevated HA levels, and the expression of HRs, coincides with periods of dopaminergic specification [
24], suggesting that HA might influence dopamine (DA) neuron generation in the ventral midbrain (VM). In rats, differentiated dopaminergic neurons are first identified at E12 by expression of Tyrosine Hydroxylase (TH), the rate-limiting enzyme for DA synthesis. The peak of DA neurogenesis is at E13. By E16, all DA cells are post-mitotic and their axons are
en route to reach forebrain structures such as the striatum and the cerebral cortex [
25],[
26].
On cortical neural stem/progenitor cell (NSPC) cultures, the effect of activating H
1 and H
2 receptors has been reported [
27]. HA increases cell proliferation by H
2R activation and has a neuronal-differentiating action mediated by H
1R stimulation, probably by rising
prospero 1 and
neurogenin 1 expression [
28] and favoring differentiation to FOXP2-positive neurons [
29]. Furthermore, HA stimulates neuronal differentiation of adult subventricular zone NSPC [
30]. The HA concentrations required to observe these effects are 100 μM to 1 mM.
Elucidating the developmental pathways that control neuronal specification in the VM is of great relevance to increase our knowledge in differentiation of dopaminergic cells. In this work, we aimed to study the effect of HA on dopaminergic development. We found that HA is detrimental to dopaminergic differentiation of NSPC in vitro, and demonstrate that HA administration in vivo at early developmental stages decreases dopaminergic induction in the VM through H1R stimulation. This study establishes the inhibitory relationship of HA to DA neuron generation during development, and provides a novel mechanism for the future treatment of Parkinson’s disease.
Discussion
In this study we report that: i) midbrain NSPC express HA receptors; ii) HA stimulus increases intracellular calcium in proliferative VM NSPC; iii) one millimolar HA promotes apoptotic death of cultured VM NSPC by activating H1R; iv) Ten μM HA increases neuronal differentiation, but 1 mM HA decreases the number of differentiated dopaminergic neurons, in a H1R-dependent fashion, on VM NSPC cultures; v) HA injection at E12 decreases dopaminergic induction in VM without altering GABA or serotonin neurons in vivo; vi) HA interferes with dopaminergic development only when administered at early developmental stages; vii) HA impaired cell proliferation in the VM in vivo and viii) the effect of HA on dopaminergic differentiation is mediated by activation of H1R.
We found that H
1 and H
2 receptors are present at both mRNA and protein levels in proliferating and differentiated cultured VM NSPC. We showed that upon HA stimulation, undifferentiated cultures of VM NSPC significantly increased the cytoplasmic Ca
2+ concentration. This data strongly suggest the presence of functional H
1R coupled to the canonical calcium response in VM NSPC, consistent with the calcium responses evoked by 100 μM HA in cortical NSPC, which is blocked by chlorpheniramine [
29], supporting the notion that H
1R activation in undifferentiated NSPC occurs in both the forebrain and midbrain. It is well established that intracellular Ca
2+ regulates neurogenesis as well as neurite/nerve growth and axonal pathfinding [
34],[
37],[
38]. In cortical NSPC, H
1R was responsible for the increased neuronal differentiation caused by HA. We explored the effect of HA on proliferation, cell death and differentiation of cultured midbrain NSPC. No significant differences on cell proliferation were found in HA-treated VM NSPC, when compared to control conditions. Regarding cell death, we observed an increasing effect of HA on apoptosis with 1 mM HA, which was clearly prevented by chlorpheniramine. We have previously reported that HA, through H
1R activation, increases differentiation of E14 cortical NSPC to neurons that are positive for FOXP2, a marker of deep cortical layers [
27],[
29]. In contrast, in this study we found that in E12 VM NSPC, 10 μM HA increased neurogenesis and 1 mM HA affected DA neuron generation. These results highlight that the effects of HA vary depending on the studied brain region and the concentration of HA used. In VM NSPC, the decrease in TH + cells was mediated by H
1R.
Previous studies have shown the expression patterns of HA-immunoreactive neurons and HRs at different stages of development [
15]. HA-immunoreactive neurons are first detected on E13 in the regions of mesencephalon and metencephalon, this expression pattern remains until E17 and gradually decreases towards birth [
15]. The expression patterns of HRs were reported at later stages of development (from E14 onwards) by
in situ hybridization [
18],[
20]. We now show by RT-PCR and Western blot the presence of H
1 and H
2 receptors in E12 cultured VM NSPC
.
Ultrasound guided-injection is a valuable technique that allows visualization and manipulation of embryos at specific developmental stages [
39]–[
41]. We did not find morphological differences between the vehicle- and HA-injected embryos, assessed by hematoxylin-eosin staining and the VM thickness, which allowed us to confidently proceed to analyze the effect of HA on midbrain development. We corroborated, by co-injections with Cell tracker, that HA reached all cells in the VM. When we evaluated neuronal differentiation by immunostaining, qRT-PCR and immunoblot, HA did not modify β-III Tubulin expression, suggesting that HA is not precluding neuronal differentiation. However, consistent with the data in VM NSPC cultures, when the limiting enzyme for DA synthesis, TH, was evaluated by immunohistochemistry, qRT-PCR and Western blot, we found significant decreases after HA application at E12, pointing out to a detrimental effect on dopaminergic neurons
in vivo. These results suggest that HA might be affecting either DA specification and/or differentiation. To study if DA specification was being affected, we analyzed the expression of the Lim homeodomain genes
Lmx1a and
Lmx1b, which are specific markers for midbrain dopaminergic precursors. Lmx1a is an early marker of dividing mesencephalic precursors in the floor plate ventricular cells at early stages of development, instructing their differentiation into the midbrain dopaminergic phenotype, while Lmx1b is essential for the generation of properly differentiated midbrain dopaminergic neurons and its regional specification [
42],[
43]. HA significantly decreased the expression levels of both markers. Pitx3, a protein important for maintenance of dopaminergic identity, also decreased in HA-injected embryos, relative to vehicle-treated animals. To further support that HA is acting on DA precursors, E10 and E12 embryos were injected either with vehicle or HA. We demonstrated that the impairing effect of HA over the dopaminergic lineage is present in both developmental stages. In sharp contrast, DA neurons were unaffected when HA was applied at E14 or E16, when most cells already differentiated to dopaminergic neurons. These results strongly support that detrimental action of HA is on VM dopaminergic neural precursors rather than early differentiated neurons.
We found that HA did not modify BrdU incorporation in cultured VM NSPC, but significantly decreased the number of ventricular pHH3-positive cells
in vivo. This different effect of HA on proliferation might be explained by the fact that BrdU was added to cultures for 3 h, and is incorporated by cells in the S phase of cell cycle, whereas pHH3 is present in cells undergoing mitoses. An additional factor to consider is that 100 μM HA caused a significant increase of BrdU incorporation in cultured cortical NSPC in the presence of daily-added 10 ng/ml FGF-2 [
27], the same conditions used here for VM NSPC. A potentiation of thymidine incorporation has also been reported for tracheal smooth muscle human cells incubated with 10 ng/ml Epidermal Growth Factor and 10 μM HA, compared to the growth factor-only condition; this increased proliferation was associated to activation of Akt with participation of Gq/11 receptors [
44]. It is possible that in cultured VM cells there are subpopulations that differentially respond to HA: some might decrease (i.e. dopaminergic precursors), while others (non-dopaminergic cells) could increase BrdU incorporation, resulting in no overall changes after HA addition. This possibility is supported by the fact that HA caused a significant decrease in the number of differentiated dopaminergic neurons both
in vitro and
in vivo.
We also analyzed the differentiation of other neuronal phenotypes present in midbrain-surrounding regions. Both serotoninergic and dopaminergic neurons arise from the ventral-most neuroepithelial progenitors, although at different rostro-caudal levels [
45]. GABAergic cells are present in the
substantia nigra pars reticulata and to some extent within the
substantia nigra pars compacta and also in the ventral tegmental area [
35]. Here, we demonstrate that the HA effect on midbrain development was selective for dopaminergic phenotype without affecting the generation of GABA neurons. In line with these findings, serotonin neurons, which are formed in the hindbrain very close to the midbrain-hindbrain boundary, were unaffected by HA.
In order to identify the cellular mechanism by which HA was exerting its action on decreasing TH + dopaminergic neurons, we co-injected HA with H
1R or H
2R antagonists. We found that only chlorpheniramine, a selective H
1R antagonist, completely prevented the impairing action of HA over DA neurons. Our data support the hypothesis that HA action is on precursor dopaminergic cells by activation of H
1R. We suggest that HA might be acting as a detrimental signal during early stages of DA specification. As we showed
in vitro, incubation with HA leads to the elevation of Ca
2+ in Nestin-positive VM NSPC, which might suggest that the mechanistic basis of HA effect over NSPC population affecting dopaminergic differentiation/specification involves intracellular Ca
2+. Interestingly, Ca
2+ signaling appears to control NSPC proliferation, regulating the switch from proliferation to neuronal differentiation [
46]. For instance, in human NSPC, mobilization of IP
3-dependent Ca
2+ stores lengthens the cell cycle and increases the number of intermediate neural progenitors [
34]. In this model, Ca
2+ controls the duration of cell cycle by increasing the level of p53 protein, a known regulator of the cyclin-dependent kinase inhibitor p21 [
47]. We have previously shown in cortical NSPC cultures the effect of HA on cell division patterns, evaluating asymmetric and symmetric divisions [
28]. In the developing VM, proliferating cells are present in close to the ventricular zone [
36]; we show that the number of mitotic cells is decreased by HA injection
in vivo, and this could be a contributing mechanism for the decreased number of dopaminergic neurons.
The effects of artificially administering HA during VM development are clear, but we did not directly assess the participation of endogenous HA on dopaminergic development for example by decreasing its levels by inhibiting Histidine decarboxylase activity; nonetheless, the injection of H
1 or H
2 receptor antagonists alone did not modify TH staining, suggesting that the endogenous HA levels are not sufficient to affect dopaminergic development. Interestingly, the participation of HA in the pathogenesis of Parkinson’s disease in adult organisms has been suggested by previous work. For example, there is an increase in brain HA content in post-mortem putamen and
substantia nigra[
48] and HA blood levels are increased in parkinsonian patients [
49]. Also, the number of histaminergic fibers innervating the
substantia nigra is increased in individuals suffering Parkinson’s disease relative to controls [
48],[
50]. In addition to these suggestive data, there is experimental evidence showing that HA can affect differentiated dopaminergic neurons in the adult brain. Direct infusion of HA in the rodent
substantia nigra leads to a selective damage of DA neurons [
51]. One of the most widely used animal model for Parkinson’s disease is the intracerebral injection of the DA neurotoxin 6-hydroxydopamine in one hemisphere. When endogenous brain HA levels were increased or decreased, 6-hydroxydopamine-induced damage was potentiated or inhibited, respectively, assessed by TH immunostaining and by the rotational test after apomorphine administration. Supporting the participation of HA in the damage induced by this neurotoxin, the H
1R antagonist pyrilamine, significantly, albeit transiently, decreased DA neuron degeneration; the H
2R antagonist cimetidine, did not modify the 6-hydroxydopamine-induced damage [
52].
Alternative mechanisms for the deleterious effects of HA on DA cells can include activation of microglial cells. In the adult
substantia nigra injection of HA generates a microglial reaction, promoting dopaminergic cell death [
51]. The possibility that microglia might contribute to DA degeneration in our model needs to be tested. There is evidence that microglia are present at this developmental stages [
53], and that activated microglial cells reduce the number of neural precursor cells by phagocytosis in the developing cerebral cortex [
54].
Competing interests
The authors declare no competing financial interests.
Authors’ contributions
IEA wrote the manuscript, analyzed the data and performed most of the experiments with help from FVR. AMH contributed to the design of experiments and discussion of results. RLG helped to perform intrauterine injections, analysis and discussion of results. DC and JADC contributed to set up techniques reviewed the manuscript and took part in the discussion of results. All authors read and approved the final manuscript. IV contributed to experiment design/supervision, reviewed the manuscript and obtained funding.